Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul 30;5(7):e11784.
doi: 10.1371/journal.pone.0011784.

CD25 appears non essential for human peripheral T(reg) maintenance in vivo

Affiliations

CD25 appears non essential for human peripheral T(reg) maintenance in vivo

Marie-Ghislaine de Goër de Herve et al. PLoS One. .

Abstract

Background: IL-2 has been reported to be critical for peripheral T(reg) survival in mouse models. Here, we examined T(reg) maintenance in a series of paediatric liver transplant recipients who received basiliximab, a therapeutic anti-CD25 monoclonal antibody.

Methodology/principal findings: FoxP3+ CD4 T cells were analyzed by flow cytometry before liver grafting and more than 9 months later. We found that in vivo CD25 blockade did not lead to T(reg) depletion: the proportion of FoxP3+ cells among CD4 T cells and the level of FoxP3 expression were both unchanged. IL-2Rbeta expression was enhanced in FoxP3+ cells both before and after basiliximab treatment, while the level of IL-2Rgamma expression was similar in T(regs) and non-T(regs). No significant change in the weak or absent expression of IL-7Ralpha and IL-15Ralpha expression on FoxP3+ cells was observed. Although the proportion of FoxP3+ cells among CD4 T cells did not vary, food allergies occurred more rapidly after liver grafting in patients who received basiliximab, raising questions as to T(reg) functionality in vivo in the absence of functional CD25.

Conclusions: CD25 appears non essential for human T(reg) peripheral maintenance in vivo. However, our results raise questions as to T(reg) functionality after therapeutic CD25 targeting.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. No significant effect of a blocking anti-CD25 antibody on the proportion of human FoxP3+ CD4 T cells in vivo.
The proportion of CD25+FoxP3+ (1A), CD25FoxP3+ (1B) and total FoxP3+ cells (1C) among CD4 T lymphocytes was determined before liver grafting and basiliximab injection, and for more than 9 months thereafter; data are means (curves) and SEM at the different time points. In 1D, the FoxP3+/FoxP3 and FoxP3hi/FoxP3 MFI ratios were used to compare the level of intracellular FoxP3 expression (see Methods). Means and SEM are shown. The Mann Whitney test was used for statistical analysis. The number of patients tested at each time point is indicated. Only statistically significant differences are indicated.
Figure 2
Figure 2. Human FoxP3+ CD4 T cells express high levels of IL-2 Rβ.
IL-2Rβ (Fig. 2A, 2B), IL-2Rγ (Fig. 2A, 2C), IL-15Rα (Fig. 2A, 2D) and IL-7Rα (Fig. 2A, 2E) expression was analyzed by flow cytometry in FoxP3+ and FoxP3 CD4 T cells before liver grafting and basiliximab injection (Figs. 2B to 2E), and at various times thereafter (2B to 2E). Fig. A shows a representative pre-graft staining profile. Figs. 2B to 2E represent the mean (SEM) MFI ratios (see Methods). The Wilcoxon test was used to compare FoxP3+ and FoxP3 CD4 T cells. The Mann Whitney test was used to analyze the time course of expression in a given cell subset. Only significant differences are indicated.

Similar articles

Cited by

References

    1. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation. 1999;67:276–284. - PubMed
    1. Du J, Yang H, Zhang D, Wang J, Guo H, et al. Structural basis for the blockage of IL-2 signaling by therapeutic antibody basiliximab. J Immunol. 2010;184:1361–1368. - PubMed
    1. Binder M, Vogtle FN, Michelfelder S, Muller F, Illerhaus G, et al. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res. 2007;67:3518–3523. - PubMed
    1. Rickert M, Boulanger MJ, Goriatcheva N, Garcia KC. Compensatory energetic mechanisms mediating the assembly of signaling complexes between interleukin-2 and its alpha, beta, and gamma(c) receptors. J Mol Biol. 2004;339:1115–1128. - PubMed
    1. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity. 2009;30:626–635. - PubMed

Publication types

MeSH terms

Substances